Example: Heart Attack

Clinical Trials on Primary Central Nervous System Lymphoma

Total 44 results

NCT04845139

Recruiting

A Case Study of Nivolumab for Relapsed/Refractory Primary Central Nervous System Lymphoma

Conditions: Refractory Central Nervous System Lymphoma, Relapsed Primary Central Nervous System Lymphoma, Primary Central Nervous System Lymphoma
NCT04831658

Recruiting

A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma

Conditions: Primary Central Nervous System Lymphoma
NCT02315326

Active, not recruiting

Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)

Conditions: Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL), Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)
NCT03188354

Recruiting

Diagnostic Assessment of 18F-fluciclovine and 18F-FDG -PET/MRI of Primary Central Nervous System Lymphoma

Conditions: Lymphoma, Non-Hodgkin, Central Nervous System Neoplasms
NCT03255018

Active, not recruiting

Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas

Conditions: Non-Hodgkin Lymphoma, Lymphoma, Diffuse Large B-Cell Lymphoma, Gray Zone Lymphoma, Primary Central Nervious System Lymphoma
NCT04737889

Recruiting

Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma

Conditions: Primary Central Nervous System Lymphoma
NCT04481815

Recruiting

Rituximab Plus Methotrexate With or Without Lenalidomide in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

Conditions: PCNSL
NCT02857426

Active, not recruiting

A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Conditions: Lymphoma
NCT01956695

Completed

Efficacy of Lenalidomide With Rituximab in Refractory or Relapse of Primary Central Nervous System Lymphoma

Conditions: Lymphoma, Relapse
NCT04070040

Recruiting

Camrelizumab for Patients With Recurrent Primary Central Nervous System Lymphoma (PCNSL)

Conditions: Primary Central Nervous System Lymphoma
NCT00293475

Recruiting

Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

Conditions: Central Nervous System Lymphoma
NCT04457869

Not yet recruiting

A Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL)

Conditions: Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma
NCT03581942

Recruiting

Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL)

Conditions: Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL)
NCT01399372

Active, not recruiting

Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma

Conditions: Chemotherapeutic Agent Toxicity, Cognitive/Functional Effects, Lymphoma, Neurotoxicity, Radiation Toxicity
NCT04253496

Not yet recruiting

Mathematic Modeling at Micro and Macroscopic Level of Primary Central Nervous System Lymphomas (PCNSL)

Conditions: Primary Central Nervous System Lymphoma (PCNSL)
NCT04129710

Recruiting

A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Conditions: Recurrent/RefractoryPrimary Central Nervous System Lymphoma (PCNSL)
NCT04083066

Recruiting

Open Randomized Prospective Clinical Study of R-FPD Versus R-MAD Regimen in the Treatment of Primary Central Nervous System Lymphoma

Conditions: Primary Central Nervous System Lymphoma
NCT01722305

Completed

Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular Lymphoma

Conditions: B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma, Central Nervous System Lymphoma, Intraocular Lymphoma, Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System, Recurrent Adult Diffuse Large Cell Lymphoma, Retinal Lymphoma
NCT02669511

Completed

PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma

Conditions: Primary Central Nervous System Lymphoma
NCT03558750

Terminated

Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System Lymphoma

Conditions: Recurrent Central Nervous System Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Central Nervous System Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
NCT00863460

Active, not recruiting

Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young Patients

Conditions: Primary Central Nervous System Lymphoma
NCT03120000

Withdrawn

PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma

Conditions: Primary Central Nervous System Lymphoma
NCT03690895

Completed

Long-term Outcome of AIDS-related Primary Central Nervous System Lymphoma Treated With High Dose Methotrexate and Combined Antiretroviral Therapy

Conditions: Central Nervous System Lymphoma, AIDS Related Lymphoma
NCT00068250

Completed

Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma

Conditions: Brain and Central Nervous System Tumors, Lymphoma
NCT02301364

Completed

Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL)

Conditions: Lymphoma, Primary Central Nervous System Lymphoma, Recurrent/Refractory Secondary Central Nervous System Lymphoma